Primary Breast Cancers are Reduced by Raloxifene

University of Pennsylvania Cancer Center
Ultima Vez Modificado: 19 de mayo del 1998

In a second analysis of the study presented yesterday, researchers found that the risk of developing breast cancer was reduced by 58% in women taking Raloxifene, compared to women receiving a placebo. This dramatic reduction was observed in postmenopausal women being treated for osteoporosis who had no history of breast cancer. The researchers conclude that there is substantial evidence for a profound reduction in the risk of developing breast cancer for patients taking Raloxifene.

Raloxifene has target-site specific estrogen agonist effects on bone and lipid an antagonist effects on breast and uterine tissue, via modulation an high affinity binding to the estrogen receptor on tumor cells.

[ Original Abstract ]

Blogs

Homeopathy: What You Should Know
by The 4Wholeness Team
July 22, 2015